Is a complete BBIO research report available?

No complete published report is available for BridgeBio Pharma, Inc. (BBIO) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

BridgeBio Pharma, Inc. (BBIO)

NASDAQ: BBIO · USD

$83.5

-2.01 (-2.4%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first BBIO analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	16.4B
Revenue (ttm)	580M
Net income (ttm)	-721.6M
EPS (ttm)	-$3.74
Shares out	196M
Volume	2,400,883
Beta	0.95
Price target	$105	+26.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 580M
Net income (ttm): -721.6M
EPS (ttm): -$3.74
Market cap: 16.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All BBIO indicators

Market & fundamental data

Available fields

211

Groups with data

Currency

USD

Showing 211 of 211 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001743881
Company name	BridgeBio Pharma, Inc.
Country	United States
Country code	US
Cusip	10806X102
Employees	839
Employees Change	109%
Employees Change Percent	14.93
Enterprise value	$17.9B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2019-06-27
Isin	US10806X1028
Last refreshed	2026-07-30
Market cap	$16.4B
Market cap category	Large-Cap
Price	$83.54
Price currency	USD
Rev Per Employee	691,249.11x
Sector	Healthcare
Sector PE	45.6
Sector PE Fwd	24.3
Sic	2834
Symbol	BBIO
Website	https://bridgebio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-4.41%
EV Sales Forward	16.68x
EV/Sales	30.91x
FCF yield	-2.72%
P/S ratio	28.24x
PS Forward	15.24x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-90.52%
EBITDA Margin	-89.6%
Gross margin	95.13%
Gross Profit	$551.7M
Gross Profit Growth	354.09%
Gross Profit Growth Q	61.92%
Gross Profit Growth3 Y	94.44%
Gross Profit Growth5 Y	129.26%
Net Income	$-721.6M
Net Income Growth Quarters	2%
Net Income Growth Years	0%
Pretax Margin	-125.78%
Profit Margin	-124.41%
Profit Per Employee	$-860,014
ROA	-27.98
Roa5y	-44.94
ROCE	-94.66
ROIC	-142.3

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	80.78%
Cagr3y	34.38%
Cagr5y	8.58%
EPS Growth Quarters	2
EPS Growth Years	0
Revenue Growth	355.17x
Revenue Growth Q	66.78x
Revenue Growth Quarters	4x
Revenue Growth Years	2x
Revenue Growth3 Y	95.36x
Revenue Growth5 Y	131.56x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.51
Assets	$1.4B
Cash	$940.2M
Current Assets	$1.2B
Current Liabilities	$816.4M
Debt	$2.5B
Equity	$-2.3B
Interest Coverage	-2.78
Liabilities	$3.6B
Long Term Assets	$129.7M
Long Term Liabilities	$2.8B
Net Cash	$-1.6B
Net Cash By Market Cap	$-9.48
Tangible Book Value	$-2.3B
Tangible Book Value Per Share	$-11.78
WACC	9.03

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.52
Inventory Turnover	1.53
Net Working Capital	$36.7M
Quick ratio	1.4
Working Capital	$424.9M
Working Capital Turnover	$1.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.99%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	80.71%
200-day SMA	71.13
3Y total return	142.71%
50-day SMA	73.5
50-day SMA vs 200-day SMA	50over200
5Y total return	50.88%
All Time High	93.42
All Time High Change	-10.57%
All Time High Date	2026-07-09
All Time Low	4.98
All Time Low Change	1,577.51%
All Time Low Date	2022-05-12
ATR	2.96
Beta	0.95
Beta1y	0.01
Beta2y	0.67
Ch YTD	9.22
High	85.79
High52	93.42
High52 Date	2026-07-09
High52ch	-10.57%
Low	83.35
Low52	42.09
Low52 Date	2025-08-06
Low52ch	98.48%
Ma50ch	13.65%
Premarket Change Percent	-4.73
Premarket Price	$81.5
Premarket Volume	122
Price vs 200-day SMA	17.45%
RSI	60.39
RSI Monthly	71.31
RSI Weekly	63.51
Sharpe ratio	1.38x
Sortino ratio	2.38
Total Return	-1.99%
Tr YTD	9.22
Tr1m	18.94%
Tr1w	1.07%
Tr3m	19.84%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	22
Analyst Count Top	16
Analyst Price Target Top	$105
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.6
Earnings Revenue Estimate	223,983,672x
Earnings Revenue Estimate Growth	102.58x
Operating Income	$-504.2M
Operating margin	-86.94
Price target	$105
Price Target Change	$26
Price Target Change Top	$25.77

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	164,812,793%
Float Percent	84.07%
Net Borrowing	932,500,000
Shares Insiders	3.95%
Shares Institutions	86.08%
Shares Out	196,036,786
Shares Qo Q	0.64%
Shares Yo Y	1.99%
Short Float	15.62%
Short Ratio	5.11
Short Shares	13.14

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-585.5M
Adjusted OCF	-584,338,000
Average Volume	3,381,435.45x
Bv Per Share	-11.64
CAPEX	$-1.2M
Ch1m	18.94
Ch1w	1.07
Ch1y	80.71
Ch3m	19.84
Ch3y	142.7
Ch5y	50.88
Ch6m	7.81
Change	-2.35%
Change From Open	-2.28
Close	85.55
Days Gap	-0.07
Depreciation Amortization	5,336,000
Dollar Volume	200,569,765.8
Earnings Date	2026-07-31
Earnings Time	amc
EBIT	$-525M
EBITDA	$-519.7M
EPS	$-3.74
F Score	2
FCF	$-445.1M
FCF EV Yield	-2.48x
FCF Per Share	$-2.27
Financing CF	848,857,000
Fiscal Year End	December
Founded	2,015
Income Tax	$435,000
Investing CF	-65,627,000
Ipr	391.4
Iprfo	172.9
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-24
Ma150	72.91
Ma150ch	14.58%
Ma20	81.97
Ma20ch	1.92%
Net CF	339,276,000
Next Earnings Date	2026-08-11
Open	85.49
Optionable	Yes
Position In Range	7.79
Ppne	22,167,000
Pre Close	85.55
Price Date	2026-07-29
Relative Volume	0.71x
Revenue	579,958,000x
SBC By Revenue	24.21x
Share Based Comp	140,384,000
Tax By Revenue	0.08x
Tr6m	7.81%
Us State	California
Volume	2,400,883
Z Score	-2.72

BridgeBio Pharma, Inc. (BBIO)

Coverage state: Market snapshot only — no published research

Generate the first BBIO analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · BBIO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BBIO indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on BBIO

Frequently asked questions